NanoBio Corp. will get an initial contract of $5.5 million and up to $5 million more to devleop its nanoemulsion technology to improve the performance of flu vaccines.
NanoBio Corp. announced Wednesday the closing of an $11 million Series C financing, including full participation from its existing investor syndicate.
Ann Arbor-based NanoBio Corp. says newly published experimental data shows that its nanoemulsion-based flu vaccine has elicited robust immunity to the flu in animal tests on ferrets.
Ann Arbor-based NanoBio Corp. said Tuesday that it had been awarded its seventh United States patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis, […]